Regulatory StrategyREG-003Publishedv1.0.0

Breakthrough/Fast Track Evidence Pack

Maximize your chances for expedited designation

~25s runtime3 evidence sources3 regulatory mappingsUpdated Dec 2025

Summary

Compiles FDA expedited program precedents, designation request strategies, and acceptance criteria analysis to support Breakthrough Therapy and Fast Track applications.

Detailed Description

The Breakthrough/Fast Track Evidence Pack helps sponsors prepare compelling requests for FDA expedited program designations. It analyzes historical Breakthrough Therapy Designation (BTD), Fast Track Designation (FTD), and Priority Review precedents to identify the evidentiary thresholds and presentation strategies associated with successful applications.

The pack evaluates your clinical data against the statutory and practical criteria for each expedited program, benchmarking your results against approved designations in the same therapeutic area. It identifies the strength and weaknesses of your current evidence package and recommends strategies to address gaps.

Deliverables include an expedited designation feasibility assessment, a designation request template pre-populated with precedent-informed content, and a comparative analysis of successful and unsuccessful designation requests in your indication.

Evidence Sources

SourceTypeDescriptionRefresh
FDA Expedited Program DatabaseREGULATORYHistorical database of Breakthrough Therapy, Fast Track, Accelerated Approval, and Priority Review designationsMonthly
Designation Request PrecedentsCURATEDCurated collection of successful and unsuccessful designation request strategies with analysisQuarterly
FDA Expedited Programs GuidanceREGULATORYFDA guidance on expedited programs for serious conditionsMonthly

Regulatory Mapping

FDAFDA-2013-D-0575

Expedited Programs for Serious Conditions: Drugs and Biologics

PRIMARY
FDASection 506(a) FD&C Act

Fast Track Designation

PRIMARY
FDASection 506(a)(2) FD&C Act

Breakthrough Therapy Designation

PRIMARY

Agent Transparency

When you run this pack, your request is processed by a pipeline of specialized AI agents. Each agent operates with a defined confidence threshold and is auditable end-to-end.

🔍

Evidence Retriever

brew-retriever-v3

Step 1

Queries curated sources for relevant evidence objects. Searches across regulatory databases, clinical registries, and scientific literature to surface the most pertinent references for the pack domain.

Confidence floor: 85%Avg latency: 4-8s
🧬

Domain Analyzer

brew-domain-analyst-v2

Step 2

Applies domain-specific reasoning and regulatory mapping. Interprets evidence in the context of FDA, ICH, and EMA frameworks and tags each finding with the relevant guidance references.

Confidence floor: 80%Avg latency: 6-12s
📊

Evidence Synthesizer

brew-synthesizer-v2

Step 3

Synthesizes findings into structured output. Combines retrieved evidence and domain analysis into a cohesive narrative with quantitative summaries, comparative tables, and actionable recommendations.

Confidence floor: 82%Avg latency: 8-15s

Output Validator

brew-validator-v1

Step 4

Validates citations, checks confidence thresholds, and ensures all referenced sources are accessible and correctly attributed. Flags any claims that fall below the confidence floor.

Confidence floor: 90%Avg latency: 2-4s

Sample Outputs

Expedited Designation Feasibility Assessment

PDF

Analysis of eligibility and evidence strength for each expedited program with recommendations

Designation Request Template

DOCX

Pre-populated designation request with precedent-informed structure and content recommendations

Precedent Designation Analysis

XLSX

Comparative analysis of designation requests in the target indication with success factors

Deliverables included

  • Expedited designation feasibility assessment
  • Breakthrough Therapy Designation request template
  • Fast Track Designation request template
  • Precedent analysis of designation decisions
  • Post-designation engagement strategy

Related Disease & Biomarker Mappings

Therapeutic AreaDisease FamilyKey BiomarkersRelevance
Cross-TherapeuticRegulatory Strategy
N/A — regulatory focus
Primary
OncologyAccelerated Approval Programs
ORRDORctDNA response
Secondary

Related Packs in Regulatory Strategy

Version History

v1.0.0CurrentNovember 14, 2025

Current release — expanded evidence sources, improved citation accuracy, and added new regulatory cross-references.

v0.9.0October 15, 2025

Beta release — validated with domain SMEs. Added sample output previews and refined confidence scoring.

v0.1.0September 15, 2025

Initial draft — core evidence retrieval pipeline and output schema established.

Need a Custom Evidence Pack?

Our enterprise team can build bespoke evidence packs tailored to your therapeutic area, regulatory strategy, or internal decision framework. Custom packs include dedicated evidence source curation, domain-specific agent tuning, and priority SLA support.

Enterprise packs are available for organizations on the BrewBio Pro or Enterprise plan.